A thrombopoietin antagonist is capable of affecting stem and progenitor cells of patients with myelofibrosis

Xiaolin Wang; David Haylock; Cing Siang Hu; Goar Mosoyan; D.A. Winkler; Ronald Hoffman

A thrombopoietin antagonist is capable of affecting stem and progenitor cells of patients with myelofibrosis

Xiaolin Wang, David Haylock, Cing Siang Hu, Goar Mosoyan, D.A. Winkler, Ronald Hoffman

Research output: Contribution to journal › Article › Other

Abstract

Aberrant thrombopoietin (TPO)/MPL signaling has been hypothesized to contribute to the pathogenesis of myelofibrosis (MF). Agents that would be capable of inhibiting this signaling pathway are possible novel therapeutic agents that might be effective for MF treatment. A peptide antagonist of TPO, LCP4, has been created which is highly antagonistic to CB CD34+ cell proliferation and differentiation induced by TPO. In this report we examined the effect of LCP4 on the proliferation of MF CD34+ cells and their differentiation to megakaryocytes (Mk).

Original language	English
Pages (from-to)	819
Number of pages	1
Journal	Blood
Volume	124
Issue number	21
Publication status	Published - 2014

Access to Document

http://www.bloodjournal.org/content/124/21/819

Cite this

@article{36c50fb882b7472ea0d0727d3fc25487,

title = "A thrombopoietin antagonist is capable of affecting stem and progenitor cells of patients with myelofibrosis",

abstract = "Aberrant thrombopoietin (TPO)/MPL signaling has been hypothesized to contribute to the pathogenesis of myelofibrosis (MF). Agents that would be capable of inhibiting this signaling pathway are possible novel therapeutic agents that might be effective for MF treatment. A peptide antagonist of TPO, LCP4, has been created which is highly antagonistic to CB CD34+ cell proliferation and differentiation induced by TPO. In this report we examined the effect of LCP4 on the proliferation of MF CD34+ cells and their differentiation to megakaryocytes (Mk).",

author = "Xiaolin Wang and David Haylock and Hu, {Cing Siang} and Goar Mosoyan and D.A. Winkler and Ronald Hoffman",

year = "2014",

language = "English",

volume = "124",

pages = "819",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "21",

}

TY - JOUR

T1 - A thrombopoietin antagonist is capable of affecting stem and progenitor cells of patients with myelofibrosis

AU - Wang, Xiaolin

AU - Haylock, David

AU - Hu, Cing Siang

AU - Mosoyan, Goar

AU - Winkler, D.A.

AU - Hoffman, Ronald

PY - 2014

Y1 - 2014

N2 - Aberrant thrombopoietin (TPO)/MPL signaling has been hypothesized to contribute to the pathogenesis of myelofibrosis (MF). Agents that would be capable of inhibiting this signaling pathway are possible novel therapeutic agents that might be effective for MF treatment. A peptide antagonist of TPO, LCP4, has been created which is highly antagonistic to CB CD34+ cell proliferation and differentiation induced by TPO. In this report we examined the effect of LCP4 on the proliferation of MF CD34+ cells and their differentiation to megakaryocytes (Mk).

AB - Aberrant thrombopoietin (TPO)/MPL signaling has been hypothesized to contribute to the pathogenesis of myelofibrosis (MF). Agents that would be capable of inhibiting this signaling pathway are possible novel therapeutic agents that might be effective for MF treatment. A peptide antagonist of TPO, LCP4, has been created which is highly antagonistic to CB CD34+ cell proliferation and differentiation induced by TPO. In this report we examined the effect of LCP4 on the proliferation of MF CD34+ cells and their differentiation to megakaryocytes (Mk).

UR - http://www.bloodjournal.org/content/124/21/819

M3 - Article

VL - 124

SP - 819

JO - Blood

JF - Blood

SN - 0006-4971

IS - 21

ER -